Company intelligence / Profile preview
Simplexia
Gothenburg, Swedensimplexia.se ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Simplexia is developing a first-in-class vaccine for genital herpes based on targeting the glycoprotein G‑2 protein unique to HSV‑2. The approach is novel, leveraging research from the University of Gothenburg. No clinical results have been published yet; the program appears to be in preclinical or early development.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineProtein (glycoprotein G-2)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Chalmers Ventures
Beyond the preview
Go deeper on Simplexia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simplexia.